Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c

Matthew A. Cavender, Benjamin M. Scirica, Itamar Raz, Ph Gabriel Steg, Darren K McGuire, Lawrence A. Leiter, Boaz Hirshberg, Jaime Davidson, Avivit Cahn, Ofri Mosenzon, Kyungah Im, Eugene Braunwald, Deepak L. Bhatt

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND: The effect of saxagliptin on cardiovascular outcomes according to different hemoglobin A1c (HbA1c) levels has not been described. Thus, we analyzed the SAVOR-TIMI 53 trial to compare the cardiovascular effects of saxagliptin vs placebo according to baseline HbA1c.

METHODS: A total of 16,492 patients with type 2 diabetes (HbA1c 6.5%-12.0% in the 6 months before randomization) and either a history of established cardiovascular disease or multiple risk factors for atherosclerosis were randomized to saxagliptin or placebo in addition to usual care. Patients were followed for a median of 2.1 years. The primary endpoint was cardiovascular death, myocardial infarction, or ischemic stroke.

RESULTS: Patients were stratified by HbA1c at randomization into the following prespecified groups:

CONCLUSIONS: Baseline HbA1c is associated with increased risk of macrovascular events but not hospitalization for heart failure. There was no heterogeneity in the effect of saxagliptin on cardiovascular events by baseline HbA1c, with cardiovascular death, myocardial infarction, or ischemic stroke neither increased nor decreased across the spectrum of baseline HbA1c values.

Original languageEnglish (US)
JournalThe American journal of medicine
Volume129
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Hemoglobins
Random Allocation
Stroke
Myocardial Infarction
Placebos
Type 2 Diabetes Mellitus
Atherosclerosis
Hospitalization
Cardiovascular Diseases
Heart Failure
saxagliptin

Keywords

  • Coronary artery disease
  • Diabetes mellitus
  • Glycated hemoglobin assay
  • Randomized clinical trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. / Cavender, Matthew A.; Scirica, Benjamin M.; Raz, Itamar; Gabriel Steg, Ph; McGuire, Darren K; Leiter, Lawrence A.; Hirshberg, Boaz; Davidson, Jaime; Cahn, Avivit; Mosenzon, Ofri; Im, Kyungah; Braunwald, Eugene; Bhatt, Deepak L.

In: The American journal of medicine, Vol. 129, No. 3, 01.03.2016.

Research output: Contribution to journalArticle

Cavender, MA, Scirica, BM, Raz, I, Gabriel Steg, P, McGuire, DK, Leiter, LA, Hirshberg, B, Davidson, J, Cahn, A, Mosenzon, O, Im, K, Braunwald, E & Bhatt, DL 2016, 'Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c', The American journal of medicine, vol. 129, no. 3. https://doi.org/10.1016/j.amjmed.2015.09.022
Cavender, Matthew A. ; Scirica, Benjamin M. ; Raz, Itamar ; Gabriel Steg, Ph ; McGuire, Darren K ; Leiter, Lawrence A. ; Hirshberg, Boaz ; Davidson, Jaime ; Cahn, Avivit ; Mosenzon, Ofri ; Im, Kyungah ; Braunwald, Eugene ; Bhatt, Deepak L. / Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. In: The American journal of medicine. 2016 ; Vol. 129, No. 3.
@article{32b8a05baf224e40bdb01d9c011bd447,
title = "Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c",
abstract = "BACKGROUND: The effect of saxagliptin on cardiovascular outcomes according to different hemoglobin A1c (HbA1c) levels has not been described. Thus, we analyzed the SAVOR-TIMI 53 trial to compare the cardiovascular effects of saxagliptin vs placebo according to baseline HbA1c.METHODS: A total of 16,492 patients with type 2 diabetes (HbA1c 6.5{\%}-12.0{\%} in the 6 months before randomization) and either a history of established cardiovascular disease or multiple risk factors for atherosclerosis were randomized to saxagliptin or placebo in addition to usual care. Patients were followed for a median of 2.1 years. The primary endpoint was cardiovascular death, myocardial infarction, or ischemic stroke.RESULTS: Patients were stratified by HbA1c at randomization into the following prespecified groups: CONCLUSIONS: Baseline HbA1c is associated with increased risk of macrovascular events but not hospitalization for heart failure. There was no heterogeneity in the effect of saxagliptin on cardiovascular events by baseline HbA1c, with cardiovascular death, myocardial infarction, or ischemic stroke neither increased nor decreased across the spectrum of baseline HbA1c values.",
keywords = "Coronary artery disease, Diabetes mellitus, Glycated hemoglobin assay, Randomized clinical trials",
author = "Cavender, {Matthew A.} and Scirica, {Benjamin M.} and Itamar Raz and {Gabriel Steg}, Ph and McGuire, {Darren K} and Leiter, {Lawrence A.} and Boaz Hirshberg and Jaime Davidson and Avivit Cahn and Ofri Mosenzon and Kyungah Im and Eugene Braunwald and Bhatt, {Deepak L.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.amjmed.2015.09.022",
language = "English (US)",
volume = "129",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c

AU - Cavender, Matthew A.

AU - Scirica, Benjamin M.

AU - Raz, Itamar

AU - Gabriel Steg, Ph

AU - McGuire, Darren K

AU - Leiter, Lawrence A.

AU - Hirshberg, Boaz

AU - Davidson, Jaime

AU - Cahn, Avivit

AU - Mosenzon, Ofri

AU - Im, Kyungah

AU - Braunwald, Eugene

AU - Bhatt, Deepak L.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - BACKGROUND: The effect of saxagliptin on cardiovascular outcomes according to different hemoglobin A1c (HbA1c) levels has not been described. Thus, we analyzed the SAVOR-TIMI 53 trial to compare the cardiovascular effects of saxagliptin vs placebo according to baseline HbA1c.METHODS: A total of 16,492 patients with type 2 diabetes (HbA1c 6.5%-12.0% in the 6 months before randomization) and either a history of established cardiovascular disease or multiple risk factors for atherosclerosis were randomized to saxagliptin or placebo in addition to usual care. Patients were followed for a median of 2.1 years. The primary endpoint was cardiovascular death, myocardial infarction, or ischemic stroke.RESULTS: Patients were stratified by HbA1c at randomization into the following prespecified groups: CONCLUSIONS: Baseline HbA1c is associated with increased risk of macrovascular events but not hospitalization for heart failure. There was no heterogeneity in the effect of saxagliptin on cardiovascular events by baseline HbA1c, with cardiovascular death, myocardial infarction, or ischemic stroke neither increased nor decreased across the spectrum of baseline HbA1c values.

AB - BACKGROUND: The effect of saxagliptin on cardiovascular outcomes according to different hemoglobin A1c (HbA1c) levels has not been described. Thus, we analyzed the SAVOR-TIMI 53 trial to compare the cardiovascular effects of saxagliptin vs placebo according to baseline HbA1c.METHODS: A total of 16,492 patients with type 2 diabetes (HbA1c 6.5%-12.0% in the 6 months before randomization) and either a history of established cardiovascular disease or multiple risk factors for atherosclerosis were randomized to saxagliptin or placebo in addition to usual care. Patients were followed for a median of 2.1 years. The primary endpoint was cardiovascular death, myocardial infarction, or ischemic stroke.RESULTS: Patients were stratified by HbA1c at randomization into the following prespecified groups: CONCLUSIONS: Baseline HbA1c is associated with increased risk of macrovascular events but not hospitalization for heart failure. There was no heterogeneity in the effect of saxagliptin on cardiovascular events by baseline HbA1c, with cardiovascular death, myocardial infarction, or ischemic stroke neither increased nor decreased across the spectrum of baseline HbA1c values.

KW - Coronary artery disease

KW - Diabetes mellitus

KW - Glycated hemoglobin assay

KW - Randomized clinical trials

UR - http://www.scopus.com/inward/record.url?scp=84975142370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975142370&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2015.09.022

DO - 10.1016/j.amjmed.2015.09.022

M3 - Article

C2 - 26524706

AN - SCOPUS:84958053809

VL - 129

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3

ER -